University of Michigan
Ann Arbor, Michigan, 48109, United States
NCT Number: NCT02629497
This study investigates the potential protective effects of fatty acid supplementation through inhibition of platelet activation. fatty acids (omega-3 and omega-6) will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls. Post-menopausal women with type 2 diabetes mellitus and healthy post-menopausal women will be treated with omega-3 and omega-6 fatty acid supplements to determine protection from platelet activation and thrombosis in this high risk population.
Looking for future studies?
Notify Me21 year–70 year
Female
Interventional
Early Phase 1
Ann Arbor, Michigan, 48109, United States
Essential fatty acids such as omega-3 and omega-6 have been shown to play important roles in regulating platelet activation, but the underlying mechanisms have not been fully elucidated as well as their true protection from thrombosis.
12-lipoxygenase oxidized fatty acids are known to play both a pro- and anti-thrombotic effect on platelets depending on the fatty acid. oxidation of arachidonic acid by 12-lipoxygenase resuts in a pro-thrombotic bioactive lipid whereas oxidation of the omega-6 fatty acid DGLA found in plant oil results in formation of a potent anti-thrombotic bioactive lipid. Determining the extent of protection from this and other bioactive lipids produced through oxygenase activity will allow for a better understanding of which fatty acid supplementation may best protect from thrombosis.
Essential fatty acids such as omega-3 (DHA/EPA) and omega-6 (DGLA) appear to be protective. However the underlying mechanism for this potential protection is not well understood. Identifying the mechanism by which these supplements protect from platelet activation may identify new approaches to preventing thrombotic events in this high risk population.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
Other names: DHA/EPA
Time frame: through study completion, an average of 1 year
decreased platelet activity ex vivo translating to protection from clot formation in vivo
Time frame: through study completion, an average of 1 year
measure altered levels of essential fatty acids in blood and platelets following treatment
Time frame: through study completion, an average of 1 year
determine the oxylipin products formed following each intervention
University of Michigan
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02373332
Cardiovascular Diseases, Diabetes Mellitus
Ann Arbor, Michigan, United States
View Trial DetailsNCT00041405
Cardiovascular Diseases, Coronary Disease
View Trial DetailsNCT07377097
Cardiovascular (CV) Risk, Cardiovascular Diseases
View Trial DetailsNCT03161678
Cardiovascular Diseases, Embolism and Thrombosis
Lancaster, Pennsylvania, United States
View Trial Details